Loading... Please wait...
Categories
New Products
-
$350.00 -
$95.00 -
$175.00 -
$550.00 -
$790.00
Our Newsletter
Product Description
BMS?833923 is an orally bioavailable, potent, and selective antagonist of the HH signaling component Smoothened (SMO). BMS?833923 inhibits the expression of downstream effectors in the hedgehog pathway (GLI1 and PTCH1) in cell lines that express wild?type and activated mutant form SMO. BMS?833923 inhibited the clonogenic growth of multiple tumor cell lines derived from patients with hematological malignancies including chronic myeloid leukemia, acute lymphocytic leukemia and acute myeloid leukemia, suggesting that targeting the hedgehog pathway may have broad therapeutic utility for patients with hematologic malignancies [1]. Phase I clinical studies showed BMS-833923 is well-tolerated as a monotherapy agent or as combined agent with [2]
Technical information:
| Chemical Formula: | C30H27N5O | |
| CAS #: | 1059734-66-5 | |
| Molecular Weight: | 473.57 | |
| Purity: | > 98% | |
| Appearance: | Light Yellow | |
| Chemical Name: | N-(2-methyl-5-((methylamino)methyl)phenyl)-4-((4-phenylquinazolin-2-yl)amino)benzamide | |
| Solubility: | Up to 200 mM in DMSO | |
| Synonyms: | XL139, BMS833923 |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder or DMSO solution at -20oC desiccated.
Reference:
| 1. | Gendreau SB, et al. Preclinical characterization of BMS?833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Mol Cancer Ther 2009; 8(12 Suppl):B192. Pubmed ID: DOI: 10.1158/1535-7163.TARG-09-B192 |
| 2. | Carol A, et al. A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma. Blood (2011) 118 (21): 3993. Pubmed ID: doi.org/10.1182/blood.V118.21.3993.3993 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.
